What Happened to the COVID-19 Vaccine Patent Waiver?
The negotiations leading to the WTO Decision proved once again the inadequacy of the debate over intellectual property rights.

COVID-19 vaccine manufacturers refusing to share samples may be the latest example of the tragedy of the “anticommons” in biomedical research.

The promise of COVID vaccines has been unevenly realized: fault lines have emerged between those able to secure doses and those left behind.

The proposal introduces precedents that will be used to justify further narrowing of TRIPS flexibilities.

For COVID treatments and diagnostics to be broadly available at affordable prices, their IP must be considered a global public good.

The use of fair, reasonable and non-discriminatory (“FRAND”) terms in the licensing of intellectual property rights could foster cooperation in pandemics.

Putting vaccine equity at the center of a pandemic treaty will already be a huge step towards global health’s decolonization.

The pandemic has laid bare the lack of regulation for the sharing of intellectual property needed for an effective and equitable response.

The COVID-19 pandemic has brought into sharp relief longstanding equity problems surrounding the allocation of newly developed vaccines.
